Efficacy and safety of switching from rituximab to biosimilar CT-P10 in rheumatoid arthritis: 72-week data from a randomized Phase 3 trial

por Shim, Seung Cheol, Božić-Majstorović, Ljubinka, Berrocal Kasay, Alfredo, El-Khouri, Elias Chalouhi, Irazoque-Palazuelos, Fedra, Cons Molina, Francisco Fidencio, Medina-Rodriguez, Francisco G, Miranda, Pedro, Shesternya, Pavel, Chavez-Corrales, Jose, Wiland, Piotr, Jeka, Slawomir, Garmish, Olena, Hrycaj, Pawel, Fomina, Natalia, Park, Won, Suh, Chang-Hee, Lee, Sang Joon, Lee, Sung Young, Bae, Yun Ju, Yoo, Dae Hyun
Publicado 2019

Comparison of biosimilar CT-P10 and innovator rituximab in patients with rheumatoid arthritis: a randomized controlled Phase 3 trial

por Park, Won, Božić-Majstorović, Ljubinka, Milakovic, Dragana, Berrocal Kasay, Alfredo, El-Khouri, Elias Chalouhi, Irazoque-Palazuelos, Fedra, Molina, Francisco Fidencio Cons, Shesternya, Pavel, Miranda, Pedro, Medina-Rodriguez, Francisco G., Wiland, Piotr, Jeka, Slawomir, Chavez-Corrales, Jose, Garmish, Olena, Linde, Thomas, Rekalov, Dmytro, Hrycaj, Pawel, Krause, Andreas, Fomina, Natalia, Piura, Olena, Abello-Banfi, Mauricio, Suh, Chang-Hee, Shim, Seung Cheol, Lee, Sang Joon, Lee, Sung Young, Kim, Sung Hwan, Yoo, Dae Hyun
Publicado 2018